Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.

CONTEXT An excess of the soluble receptor, fms-like tyrosine kinase 1 (sFlt-1) may contribute to maternal vascular dysfunction in women with preeclampsia by binding and thereby reducing concentrations of free vascular endothelial growth factor and placental growth factor (PlGF) in the circulation. The putative stimulus for increased sFlt-1 during preeclampsia, placental hypoxia due to poor perfusion, is common to both preeclampsia and idiopathic intrauterine growth restriction. However, the latter condition occurs without maternal vascular disease. OBJECTIVE We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates. STUDY DESIGN This was a case-control study using banked samples. Groups of women with SGA neonates (birth weight centile < 10th) and women with preeclampsia were matched to separate sets of normal pregnancy controls based on gestational age at blood sampling (serum) or gestational age at delivery (placenta). RESULTS sFlt-1 levels were higher in preeclamptics than controls (serum, P < 0.0001; placental protein, P = 0.03; placental mRNA, P = 0.007) but not increased in SGA pregnancies. PlGF was lower in both preeclampsia (serum, P < 0.0001; placental protein, P = 0.05) and SGA (serum, P = 0.0008; placental protein, P = 0.03) compared with their controls. PlGF in preeclampsia and SGA groups did not differ. CONCLUSIONS These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.

[1]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[2]  Asif Ahmed,et al.  Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.

[3]  H. Ho,et al.  Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. , 2001, American journal of obstetrics and gynecology.

[4]  F. de Wolf,et al.  Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. , 1987, British journal of obstetrics and gynaecology.

[5]  A. Luttun,et al.  Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders , 2003, Journal of thrombosis and haemostasis : JTH.

[6]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[7]  J. Cutler,et al.  Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy , 2003, Hypertension in pregnancy.

[8]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  L. Poston,et al.  A longitudinal study of biochemical variables in women at risk of preeclampsia. , 2002, American journal of obstetrics and gynecology.

[10]  G. Lash,et al.  Vascular Endothelial Growth Factor and Placental Growth Factor Release in Cultured Trophoblast Cells Under Different Oxygen Tensions , 2003, Growth factors.

[11]  M. Wolf,et al.  Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. , 2005, Placenta.

[12]  I. Crocker,et al.  An Image Analysis Technique for the Investigation of Variations in Placental Morphology in Pregnancies Complicated by Preeclampsia With and Without Interauterine Growth Restriction , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[13]  C. Oudejans,et al.  Plasma Placenta Growth Factor Levels in Midtrimester Pregnancies , 2001, Obstetrics and gynecology.

[14]  J. Kingdom,et al.  Oxygen and placental villous development: origins of fetal hypoxia. , 1997, Placenta.

[15]  O. Carpén,et al.  Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. , 2001, Molecular human reproduction.

[16]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[17]  J. Kingdom,et al.  Oxygen and placental vascular development. , 1999, Advances in experimental medicine and biology.

[18]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[19]  S. Quaggin,et al.  The role of VEGF-A in glomerular development and function , 2004, Current opinion in nephrology and hypertension.

[20]  B. Sibai,et al.  Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. , 2000, American journal of obstetrics and gynecology.

[21]  H. Augustin,et al.  Prospective Analysis of Placenta Growth Factor (PlGF) Concentrations in the Plasma of Women with Normal Pregnancy and Pregnancies Complicated by Preeclampsia , 2004, Hypertension in pregnancy.

[22]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  C. Hubel,et al.  Is oxidative stress the link in the two-stage model of pre-eclampsia? , 1999, The Lancet.

[24]  J. Jiang,et al.  Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[25]  Robert N. Taylor,et al.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.

[26]  C. Sibley,et al.  L-Arginine transport across the basal plasma membrane of the syncytiotrophoblast of the human placenta from normal and preeclamptic pregnancies. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  D. Pappin,et al.  Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. , 1998, Molecular human reproduction.

[28]  S. Kōzuma,et al.  Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.

[29]  S. Pecorelli,et al.  Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight , 1989, British journal of obstetrics and gynaecology.

[30]  N. Bersinger,et al.  Second‐ and third‐trimester serum levels of placental proteins in preeclampsia and small‐for‐gestational age pregnancies , 2004, Acta obstetricia et gynecologica Scandinavica.

[31]  J. Brosens,et al.  The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. , 2002, American journal of obstetrics and gynecology.

[32]  S. Hsu,et al.  Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. , 2006, Placenta.

[33]  Shakil Ahmad,et al.  Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. , 2000, Placenta.

[34]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[35]  Gynecologists,et al.  Intrauterine growth restriction. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  M. Wolf,et al.  Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.

[37]  W. B. Robertson,et al.  FETAL GROWTH RETARDATION AND THE ARTERIES OF THE PLACENTAL BED , 1977, British journal of obstetrics and gynaecology.

[38]  J. Foidart,et al.  Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.

[39]  M. Shibuya Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). , 2001, The international journal of biochemistry & cell biology.

[40]  F. de Wolf,et al.  Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension. , 1981, British journal of obstetrics and gynaecology.

[41]  T. H. Wang,et al.  Preeclampsia is associated with reduced serum levels of placenta growth factor. , 1998, American journal of obstetrics and gynecology.